Topotecan today

T Lynch

Editorial

T Lynch. J Clin Oncol. 1996 Dec.

. 1996 Dec;14(12):3053-5.

doi: 10.1200/JCO.1996.14.12.3053.

T Lynch

No abstract available

Comment on

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, Ten Bokkel Huinink WW. Creemers GJ, et al. J Clin Oncol. 1996 Dec;14(12):3056-61. doi: 10.1200/JCO.1996.14.12.3056. J Clin Oncol. 1996. PMID: 8955650 Clinical Trial.
Phase I and pharmacologic study of topotecan in patients with impaired renal function.
O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, Chen TL, Sartorius S, Grochow LB. O'Reilly S, et al. J Clin Oncol. 1996 Dec;14(12):3062-73. doi: 10.1200/JCO.1996.14.12.3062. J Clin Oncol. 1996. PMID: 8955651 Clinical Trial.
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC. Rowinsky EK, et al. J Clin Oncol. 1996 Dec;14(12):3074-84. doi: 10.1200/JCO.1996.14.12.3074. J Clin Oncol. 1996. PMID: 8955652 Clinical Trial.